Overlapping Transcriptional Programs Regulated by the Nuclear Receptors Peroxisome Proliferator-Activated Receptor α, Retinoid X Receptor, and Liver X Receptor in Mouse Livers⃞
- Steven P. Anderson1,
- Corrie Dunn,
- Ashley Laughter,
- Lawrence Yoon,
- Cynthia Swanson,
- Thomas M. Stulnig,
- Knut R. Steffensen,
- Roshantha A.S. Chandraratna,
- Jan-Åke Gustafsson and
- J. Christopher Corton
- Investigative Toxicology and Pathology Group, Safety Assessment, GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina (S.A.P, L.Y.); Division of Biological Science, CIIT Centers for Health Research, Research Triangle Park, North Carolina (C.D., A.L., C.S., J.C.C.); Department of Internal Medicine III, University of Vienna, and Center of Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria (T.M.S.); Departments of BioSciences and Medical Nutrition, Novum, Karolinska Institute, Huddinge, Sweden (K.R.S., J.-Å.G.); Departments of Chemistry and Biology, Retinoid Research, Allergan Inc., Irvine, California (R.A.S.C.); and ToxicoGenomics, Chapel Hill, North Carolina (J.C.C.)
- Address correspondence to:
Dr. J. Christopher Corton, ToxicoGenomics, 209 Silver Creek Trail, Chapel Hill, NC 27514. E-mail: ccorton{at}msn.com
Abstract
Lipid homeostasis is controlled in part by the nuclear receptors peroxisome proliferator (PP)-activated receptor α (PPARα) and liver X receptor (LXR) through regulation of genes involved in fatty acid and cholesterol metabolism. Exposure to agonists of retinoid X receptor (RXR), the obligate heterodimer partner of PPARα, and LXR results in responses that partially overlap with those of PP. To better understand the gene networks regulated by these nuclear receptors, transcript profiles were generated from the livers of wild-type and PPARα-null mice exposed to the RXR pan-agonist 3,7-dimethyl-6S,7S-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]-2E,4E-heptadienoic acid (AGN194,204) or the PPAR pan-agonist WY-14,643 (WY; pirinixic acid) and compared with the profiles from the livers of wild-type and LXRα/LXRβ-null mice after exposure to the LXR agonist N-(2,2,2-trifluoroethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl)phenyl] sulfonamide (T0901317). All 218 WY-regulated genes altered in wild-type mice required PPARα. Remarkably, ∼80% of genes regulated by AGN194,204 required PPARα including cell-cycle genes, consistent with AGN-induced hepatocyte proliferation having both PPARα-dependent and -independent components. Overlaps of ∼31 to 62% in the transcript profiles of WY, AGN194,204, and T0901317 required PPARα and LXRα/LXRβ for statistical significance. Ofthe 50 overlapping genes regulated by T0901317 and WY, all but one were regulated in a similar direction. These results 1) identify new transcriptional targets of PPARα and RXR important in regulating lipid metabolism and liver homeostasis, 2) illustrate the importance of PPARα in regulation of gene expression by a prototypical PP and by an RXR agonist, and 3) provide support for an axis of PPARα-RXR-LXR in which agonists for each nuclear receptor regulate an overlapping set of genes in the mouse liver.
Footnotes
-
This work was supported in part by National Institute of Environmental Health Sciences grant ES09775-01 (to J.C.C.), a Marie Curie Fellowship of the European Community program Human Potential (contract number HPMF-CT-2000-00898) (to T.M.S.), and the Swedish Science Council and KaroBio AB (to J.-Å.G.).
-
ABBREVIATIONS: NR, nuclear receptor; PPAR, peroxisome proliferator-activated receptor; PP, peroxisome proliferator; RXR, retinoid X receptor; LXR, liver X receptor; PCR, polymerase chain reaction; PXR, pregnane X receptor; ACO, acyl-CoA oxidase; BrdU, 5-bromo-2′-deoxyuridine; APP, acute phase protein; Cdk, cyclin-dependent kinase; MPF, maturation promoting factor; WY, WY-14,643 [pirixinic acid (4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thioacetic acid)]; T1317, T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl)phenyl]sulfonamide]; LGD1069, targretin; AGN, AGN194,204 (3,7-dimethyl-6S,7S-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]-2E,4E-heptadienoic acid).
-
↵s⃞ The online version of this article (available at http://molpharm.aspetjournals.org) contains four supplemental tables.
-
↵1 Current address: Bayer Corporation, Research Triangle Park, NC 27709.
-
- Received July 27, 2004.
- Accepted September 14, 2004.
- The American Society for Pharmacology and Experimental Therapeutics



